Maria G Zavala-Cerna

Dr. Maria G Zavala-Cerna

Universidad Autónoma de Guadalajara, Guadalajara, Jalisco, Mexico
orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 February 2014 in Disease Markers
Verified
Journal Article
Open access
PDF file
OTOlivia Torres-Bugarín
Olivia Torres-Bugarín
MZMaria G Zavala-Cerna
Maria G Zavala-Cerna
ANArnulfo Hernan Nava-Zavala
Arnulfo Hernan Nava-Zavala
AFAurelio flores-garcia
Aurelio flores-garcia
MRMaría Luisa Ramos-Ibarra
María Luisa Ramos-Ibarra
The use of biomarkers as tools to evaluate genotoxicity is increasing recently. Methods that have been used previously to evaluate genomic instability are frequently expensive, complicated, and invasive. The micronuclei (MN) and nuclear abnormalities (NA) technique in buccal cells offers a great opportunity to evaluate in a clear and precise way the appearance of genetic damage whether it is present as a consequence of occupational or environmental risk. This technique is reliable, fast, relatively simple, cheap, and minimally invasive and causes no pain. So, it is well accepted by patients; it can also be used to assess the genotoxic effect derived from drug use or as a result of having a chronic disease. Furthermore the beneficial effects derived from changes in life style or taking additional supplements can also be evaluated. In the present paper, we aim to focus on the explanation of MN test and its usefulness as a biomarker; we further give details about procedures to perform and interpret the results of the test and review some factors that could have an influence on the results of the technique.

29 March 2018 in Journal of Immunology Research
Verified
Journal Article
Open access
PDF file
María Cristina Morán MoguelMaría Cristina Morán Moguel
María Cristina Morán Moguel
SRStefania Petarra-Del Rio
Stefania Petarra-Del Rio
EMEvangelina E. Mayorquin-Galvan
Evangelina E. Mayorquin-Galvan
MZMaria G Zavala-Cerna
Maria G Zavala-Cerna
Rheumatoid arthritis (RA) is a systemic autoimmune disease with severe joint inflammation and destruction associated with an inflammatory environment. The etiology behind RA remains to be elucidated; most updated concepts include the participation of environmental, proteomic, epigenetic, and genetic factors. Epigenetic is considered the missing link to explain genetic diversification among RA patients. Within epigenetic factors participating in RA, miRNAs are defined as small noncoding molecules with a length of approximately 22 nucleotides, capable of gene expression modulation, either negatively through inhibition of translation and degradation of the mRNA or positively through increasing the translation rate. Over the last decade and due to the feasibility of the identification of miRNAs among different tissues and compartments, they have been proposed as biomarkers for diagnosis, prognosis, and response to treatment in different pathologies. Nevertheless, miRNAs seem to be important regulators of networks instead of single genes; their hypothetical use as biomarkers needs to rely on a functional integrative description of their effects in the biological process of autoimmune conditions which until now is missing. Therefore, we underwent a bibliographic search for review and original articles related to miRNAs and their possible implications in rheumatoid arthritis. We found 48 different studies using the key words “miRNAs” or “micro-RNAs” and “rheumatoid arthritis” with restriction of publication dates from 2011 to 2016, in humans, using the English language. After a critical reading, we provide in this paper a functional view with respect to miRNA biogenesis, interaction with targets that are expressed in specific cells and tissues, during different stages of inflammatory responses associated with RA, and recognized specific areas where miRNAs might also have a pathogenic role but remain undescribed. Our results will be useful in designing future research projects that can support miRNAs as biomarkers or therapeutic targets in RA.

5 June 2020 in Canadian Journal of Infectious Diseases and Medical Microbiology
Verified
Journal Article
Open access
PDF file
MZMaria G Zavala-Cerna
Maria G Zavala-Cerna
MSMidrori Segura-Cobos
Midrori Segura-Cobos
RGRicardo Gonzalez
Ricardo Gonzalez
IZIsidro G. Zavala-Trujillo
Isidro G. Zavala-Trujillo
SNSilvia F. Navarro-Perez
Silvia F. Navarro-Perez
FSFernando A. Satoscoy-Tovar
Fernando A. Satoscoy-Tovar
Background. Urinary tract infections (UTIs) affect up to 150 million individuals annually worldwide, mainly due to Escherichia coli (E. coli) and Klebsiella. The emergence and spread of multidrug-resistant (MDR) bacteria are increasing, representing one of the biggest threats for human health. The objective of our study was to describe antimicrobial patterns of resistance and identify risk factors associated with MDR uropathogens. Methods. We conducted a cross-sectional study in 296 patients with community-acquired UTI who underwent clinical and microbiologic analysis, and clinical associations to MDR uropathogens were investigated. Findings. Microbiological analysis included E. coli (55%), ESBL-E. coli (26%), Enterococcus (6%), Klebsiella (5%), and others (8%). Higher frequencies of MDR bacteria were found among ESBL-E. coli, with resistance to ampicillin (100%), ceftriaxone (96%), gentamicin (57%), ciprofloxacin (89%), and TMP/SMX (53%). However, they were sensitive to fosfomycin (6.6%), nitrofurantoin (1.3%), and carbapenems (0%). Fosfomycin MIC90 for ESBL-E. coli was 5.78 μg/mL. The only clinical variable with significant association to ESBL producers was the presence of comorbidities: hypertension and type 2 diabetes mellitus with an OR (95%CI) of 2.51.3−4.9p<0.01 and 2.81.2−6.7p<0.05, respectively. Conclusions. In the majority of cases, resistance rates to commonly prescribed antimicrobials in UTIs were high, except for fosfomycin, nitrofurantoin, and carbapenems. To provide appropriate treatment, both the identification of risk factors and the uropathogen would be important. An active surveillance in UTIs in the community is required since the proportion of ESBL producers is increasing.

21 May 2014 in Clinical Reviews in Allergy & Immunology
Verified
Journal Article
Closed access
PDF file
MZMaria G Zavala-Cerna
Maria G Zavala-Cerna
EMErika Aurora Martínez-García
Erika Aurora Martínez-García
OTOlivia Torres-Bugarín
Olivia Torres-Bugarín
BRBenjamín Rubio-Jurado
Benjamín Rubio-Jurado
CRCarlos Riebeling
Carlos Riebeling
ANArnulfo Hernan Nava-Zavala
Arnulfo Hernan Nava-Zavala

15 November 2024 in Microorganisms
Verified
Journal Article
Open access
PDF file
ARAna Paula Ruiz Lievano Ana Ruiz
Ana Paula Ruiz Lievano Ana Ruiz
FCFernando Cervantes-Flores
Fernando Cervantes-Flores
ATAlessandro Nava Torres
Alessandro Nava Torres
PMPaulo Javier Carbajal Morales
Paulo Javier Carbajal Morales
LVLuisa Fernanda Villaseñor
Luisa Fernanda Villaseñor
MZMaria G Zavala-Cerna
Maria G Zavala-Cerna
Community-acquired urinary tract infections account for 15% of all outpatient use of antibiotics, and women are primarily affected; the major causative microorganism is uropathogenic Escherichia coli (E. coli). Treatment is indicated for cystitis and pyelonephritis and includes B-lactams (amoxicillin-clavulanic acid or third-generation cephalosporins), fluoroquinolones (ciprofloxacin or levofloxacin), nitrofurantoin, fosfomycin, and trimethoprim–sulfamethoxazole. Resistance to antibiotic treatment is of concern; several mechanisms have been associated with the acquisition of genes that confer antimicrobial resistance to fluoroquinolones, which are often associated with other patterns of resistance, especially in extended-spectrum beta-lactamase (ESBL) producers. Several studies have addressed the prevalence of uropathogens producing ESBLs, but only a few have focused on fluoroquinolone resistance, and, to our knowledge, none have addressed the prevalence of phylotypes or genes responsible for antimicrobial resistance to fluoroquinolones. The focus of the present review was to analyze recently published papers that described the E. coli phylotype causing community-acquired UTIs in association with fluoroquinolone resistance.

1 March 2021 in Seizure: European Journal of Epilepsy
Verified
Journal Article
Closed access
ARAdrian Rodriguez-Hernandez
Adrian Rodriguez-Hernandez
JOJavier Ortiz-Orendain
Javier Ortiz-Orendain
LALucia E. Alvarez-Palazuelos
Lucia E. Alvarez-Palazuelos
LLLaura Gonzalez Lopez
Laura Gonzalez Lopez
JGJorge I. Gamez-Nava
Jorge I. Gamez-Nava
MZMaria G Zavala-Cerna
Maria G Zavala-Cerna